SCYNEXIS, Inc. (NASDAQ: SCYX) has begun dosing participants in a Phase 1 single‑ascending‑dose (SAD) and multiple‑ascending‑dose (MAD) trial of its intravenous formulation of SCY‑247, a second‑generation triterpenoid antifungal designed to treat invasive candidiasis and serve as a prophylaxis for invasive fungal disease.
The trial is the first clinical study of the IV SCY‑247 formulation and represents a critical step toward regulatory approval and future revenue generation for SCYNEXIS’s hospital‑based antifungal platform. SCY‑247 received Qualified Infectious Disease Product (QIDP) designation on January 21, 2026 and has also been granted Fast Track status, both of which accelerate the development and review process.
SCYNEXIS has shifted its focus from the outpatient vulvovaginal candidiasis (VVC) market to high‑potential hospital‑based indications since October 2022. The IV formulation builds on the company’s first‑generation platform, ibrexafungerp, and follows positive data for the oral SCY‑247 formulation reported in September 2025.
"An IV formulation of SCY‑247 would provide additional flexibility for the optimal management of patients with invasive candidiasis and we are excited by the achievement of this important development milestone, which moves this innovative antifungal closer towards meeting the needs of patients suffering from difficult to treat severe fungal diseases," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS.
SCYNEXIS is exploring non‑dilutive funding opportunities to support the SCY‑247 program and has received a 180‑day Nasdaq extension to regain compliance with minimum bid price requirements, reflecting ongoing financial pressures. Despite these headwinds, the company expects Phase 1 data in 2026 and remains focused on expanding its hospital‑based antifungal platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.